DrugBiological
Ipilimumab clinical trials
Also written Yervoy, BMS-734016 and MDX-010.
- studies test it
- 592
- open now
- 76
- in phase 3
- 59
- first study started
- 2002
Keep track of what changes. Save the Ipilimumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Ipilimumab
- 509
Brand
- Yervoy
- 323
Development codes
- BMS-734016
- 248
- MDX-010
- 213
Combined with it in one product
Biosimilars in development
- CS1002
- 3
Studies by the year they started
591 studies that test it; most in 2017 (69); 1 more planned to start later
| Year | Studies |
|---|---|
| 2002 | 4 |
| 2003 | 6 |
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 6 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 8 |
| 2010 | 9 |
| 2011 | 16 |
| 2012 | 34 |
| 2013 | 24 |
| 2014 | 29 |
| 2015 | 33 |
| 2016 | 41 |
| 2017 | 69 |
| 2018 | 69 |
| 2019 | 53 |
| 2020 | 48 |
| 2021 | 33 |
| 2022 | 30 |
| 2023 | 15 |
| 2024 | 19 |
| 2025 | 12 |
| 2026 | 22 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 11
- Phase 1
- 235
- Phase 2
- 368
- Phase 3
- 59
- Phase 4
- 5
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 160 · Other 432
Bristol-Myers Squibb (107) · National Cancer Institute (NCI) (50) · M.D. Anderson Cancer Center (41) · H. Lee Moffitt Cancer Center and Research Institute (14) · Dana-Farber Cancer Institute (13) · Memorial Sloan Kettering Cancer Center (13) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (12) · The Netherlands Cancer Institute (11)
Often tested with
Tested in the same studies.
Nivolumab (290) · Pembrolizumab (25) · Cabozantinib (15) · Relatlimab (14) · Paclitaxel (14) · Carboplatin (12) · Cisplatin (10) · Gemcitabine (9)
Studies
Open first, then newest update. How each study uses Ipilimumab is read from its arms, and is right about nine times in ten.
Testing it · 592
- A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)RecruitingPhase 1/2Bristol-Myers SquibbNCT07291076Written as Ipilimumab
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT03866382Written as Ipilimumab
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT05112601Written as Ipilimumab
- Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingPhase 2/3Yao HongweiNCT07879586Written as Ipilimumab & Sintilimab
- Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingPhase 2/3Yao HongweiNCT07879599Written as Ipilimumab & Sintilimab
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT05896839Written as Ipilimumab
- Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)RecruitingPhase 2Mark BernardNCT07770100Written as Ipilimumab
- Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT06747845Written as Ipilimumab
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06594991Written as Ipilimumab
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)RecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07430202Written as Ipilimumab
- The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.Not yet recruitingPhase 3Guliz OzgunNCT07338981Written as Nivolumab & Ipilimumab
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerRecruitingPhase 2The Netherlands Cancer InstituteNCT03026140Written as Ipilimumab
- Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or OlderNot yet recruitingPhase 1University of Southern CaliforniaNCT07838974Written as Ipilimumab
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535Written as Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05048212Written as Ipilimumab
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingPhase 2SWOG Cancer Research NetworkNCT04511013Written as Ipilimumab
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)RecruitingPhase 2Brian RiniNCT07188896Written as Ipilimumab
- Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06683755Written as Ipilimumab
- Cryoablation+Ipilimumab+Nivolumab in MelanomaRecruitingPhase 2Massachusetts General HospitalNCT05779423Written as Ipilimumab
- Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular CarcinomaRecruitingPhase 2University of Texas Southwestern Medical CenterNCT07689175Written as Ipilimumab (3 mg/kg)
See all 592 studies that test Ipilimumab →
Given in every arm · 132 — Ipilimumab is usual care beside what is tested
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686Written as Ipilimumab
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)RecruitingPhase 1/2Bristol-Myers SquibbNCT07293351Written as Ipilimumab
- ONO-4538 Phase II Rollover Study (ONO-4538-98)RecruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT04566380Written as Ipilimumab
- Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesRecruitingPhase 1/2Melanoma and Skin Cancer Trials LimitedNCT06163820Written as Ipilimumab
- Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)RecruitingPhase 2Melanoma Institute AustraliaNCT03340129Written as Ipilimumab
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruitingPhase 1/2PfizerNCT07227415Written as Ipilimumab
- Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.RecruitingPhase 1/2PfizerNCT07227012Written as Ipilimumab
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsRecruitingPhase 1Arcus Biosciences, Inc.NCT05536141Written as Ipilimumab
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingPhase 1National Cancer Institute (NCI)NCT03816345Written as Ipilimumab
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsRecruitingPhase 1ExelixisNCT05176483Written as Ipilimumab
- A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)RecruitingPhase 1M.D. Anderson Cancer CenterNCT07401875Written as ipilimumab
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisRecruitingPhase 1/2Neonc Technologies, Inc.NCT06047379Written as Ipilimumab
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Ipilimumab
- A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07532902Written as Ipilimumab
- iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable MelanomaNot yet recruitingPhase 3Scancell LtdNCT07815574Written as Nivolumab & Ipilimumab
- Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyNot yet recruitingPhase 1/2BreakBio CorpNCT07762703Written as Ipilimumab 2.5 mg
- Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyNot yet recruitingPhase 1/2BreakBio CorpNCT07762716Written as Ipilimumab 2.5 mg
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialRecruitingPhase 3NRG OncologyNCT07166406Written as Ipilimumab
- A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingPhase 1Bristol-Myers SquibbNCT07195682Written as Ipilimumab
- Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialRecruitingPhase 1/2University of Michigan Rogel Cancer CenterNCT06866262Written as Ipilimumab
Showing 20 of 132.
As the comparator · 17 — what is tested is compared with Ipilimumab
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingPhase 3Immatics US, Inc.NCT06743126Written as ipilimumab
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingPhase 1Shanghai Henlius BiotechNCT07176650Written as Yervoy
- MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaActive, not recruitingPhase 3AstraZenecaNCT06097728Written as Ipilimumab
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02506153Written as Ipilimumab
- Comparative Pharmacokinetics of SHR-8068 and Ipilimumab in Healthy Chinese MenCompletedPhase 1The Affiliated Hospital of Qingdao UniversityNCT07852325Written as Ipilimumab
- Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop TrialActive, not recruitingPhase 2ECOG-ACRIN Cancer Research GroupNCT04462406Written as Ipilimumab
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaCompletedPhase 2Immunocore LtdNCT03070392Written as Ipilimumab
- A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedPhase 2PfizerNCT05926960Written as ipilimumab
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaActive, not recruitingPhase 2/3IDEAYA BiosciencesNCT05987332Written as Ipilimumab
- Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialSuspendedPhase 2Michael B. Atkins, MDNCT05928806Written as Ipilimumab
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)CompletedPhase 1/2Hoffmann-La RocheNCT05116202Written as Ipilimumab
- A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male VolunteersCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT04868760Written as Ipilimumab
- Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic MelanomaCompletedPhase 3The Netherlands Cancer InstituteNCT02278887Written as Ipilimumab infusion
- Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell CancerCompletedPhase 1Claire VerschraegenNCT03798639Written as Ipilimumab
- A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic MelanomaCompletedPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02857569Written as Ipilimumab IV
- A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaCompletedPhase 2Bristol-Myers SquibbNCT02996110Written as Ipilimumab
- Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)TerminatedPhase 1/2Institut Claudius RegaudNCT03354962Written as Nivolumab + Ipilimumab
Codes
What other systems call Ipilimumab · ClinicalTrials.gg INT006640
- MeSH (NLM) D000074324IpilimumabConfirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) 6T8C155666IPILIMUMABConfirmed FDA, Wikidata
- RxNorm 1094833Confirmed FDA, Wikidata
- Wikidata Q2459042ipilimumabConfirmed FDA, Wikidata
- NCI Thesaurus C2654IpilimumabOne source FDA
- DrugBank DB06186One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000074324 | Ipilimumab | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | 6T8C155666 | IPILIMUMAB | Confirmed FDA, Wikidata |
| RxNorm | 1094833 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2459042 | ipilimumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C2654 | Ipilimumab | One source FDA |
| DrugBank | DB06186 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.